Administration of medroxyprogesterone acetate IP in advanced cancer with peritoneal metastases and ascitic effusion generates considerably higher drug plasma levels than those observed after PO or IM treatment. Comparison of areas under the time-concentration curves (AUC) with reference to the three
High-dose medroxyprogesterone acetate in advanced ovarian cancer
β Scribed by M. A. QUINN; R. M. ROME; P. GRANT; R. S. PLANNER
- Book ID
- 109085230
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 202 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1048-891X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high
Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is